Wegovy for Prediabetes: Evidence, Eligibility, Coverage
Wegovy is not FDA approved for prediabetes. It is approved for weight loss, heart risk and MASH liver disease. Some doctors prescribe it when one of those uses also applies. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.
- Active ingredient
- semaglutide
- How it is taken
- weekly injection or daily tablet
- Approved for
- Weight loss, heart risk and MASH liver disease
- Best result (STEP 1)
- 14.9% weight loss
Wegovy in brief
Its half-life is about 1 week: after 7 d half is gone, and after five half-lives (35 d) roughly 3% is still there.
In STEP 1 over 68 weeks, the figure was 14.9% of body weight, compared with 2.4% on placebo.
In US dollars, monthly prices include list price and self-pay offers, each taken from the maker's price page.
Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.
Who qualifies?
| Who sets the rule | Who qualifies |
|---|---|
| FDA label | It lowers heart risk in adults who have heart disease plus obesity or overweight, cutting the chance of a heart attack, stroke, or death linked to the heart (injection and tablets). |
| FDA label | Adults and children 12 and older with obesity, or adults with overweight and a weight-related condition, can use it to lose weight over the long term and keep it off with diet and activity. |
| FDA label | MASH liver disease in adults with moderate to advanced scarring (no cirrhosis) is what it treats (injection). |
| FDA label | Approval for adults covers the tablets for both weight loss and heart risk. |
| Medicare GLP-1 Bridge | BMI 35 or higher, no condition needed |
| Medicare GLP-1 Bridge | One of these must apply along with a BMI of 30 or higher: heart failure, uncontrolled blood pressure, CKD 3a+ |
| Medicare GLP-1 Bridge | You need BMI 27 or higher, plus prediabetes, a past heart attack or stroke, or PAD |
| Typical commercial plan (Aetna policy) | BMI 30 or higher |
| Typical commercial plan (Aetna policy) | BMI 27 or higher with a weight-related condition |
| Typical commercial plan (Aetna policy) | first comes a diet and activity program that lasts 6 months |
Sources: FDA label (DailyMed), medicare.gov 1 2, aetna.com.
Trial results for Wegovy in prediabetes
Not a single trial signed up only people with prediabetes. Those studied were adults with obesity or overweight, and diabetes was not one of their conditions.
| Trial | Medicine | Who took part | Length | People | Main result | Comparison |
|---|---|---|---|---|---|---|
| STEP 1 | Wegovy | Adults with obesity or overweight, without diabetes | 68 weeks | 1,961 | 14.9% weight loss | 2.4% on placebo |
| OASIS 4 | Wegovy | Adults with obesity or overweight, without diabetes | 64 weeks | 307 | 13.6% weight loss | 2.4% on placebo |
Source of the trial data: STEP 1 (FDA label (DailyMed)).
What is different for prediabetes?
| What changes | What the label says |
|---|---|
| Hypoglycemia | Low blood sugar is more likely if you use it with insulin or a sulfonylurea, and those doses may need to be lowered. |
| Taken with insulin or sulfonylureas | Using it together with insulin or a sulfonylurea raises the chance of low blood sugar, and those doses may need lowering. |
According to the FDA labels: FDA label (DailyMed).
Warnings taken from the label: DailyMed FDA label.
Coverage for prediabetes
Medicare Part D does not pay for a GLP-1 used only for weight loss.
Qualifying under the Medicare GLP-1 Bridge rules puts Wegovy on the program list at $50 per month.
Medicaid usually requires prior authorization for weight-loss GLP-1s in places where it covers them.
Sources: humana.com, CMS, KFF.
- Wegovy Coupon and Savings Card
- Wegovy Cost
- Wegovy Cost Without Insurance
- Wegovy Cost With Insurance
- Cheapest Way to Get Wegovy
- Wegovy Patient Assistance
- Is Wegovy Covered by Insurance? Criteria, Copay, Appeal
- Does Medicare Cover Wegovy? Criteria, Copay, How to Appeal
- Does BCBS Cover Wegovy? Coverage by State Plan, PA Rules, Appeals
Alternatives for prediabetes
| Medicine | For prediabetes | How it is taken | Trial result |
|---|---|---|---|
| Wegovy | Not a listed use | weekly injection or daily tablet | 14.9% weight loss |
 Ozempic | Not a listed use | weekly injection | Not listed |
 Rybelsus | Not a listed use | daily tablet | Not listed |
 Mounjaro | Not a listed use | weekly injection | Not listed |
 Zepbound | Not a listed use | weekly injection | 20.9% weight loss |
 Foundayo | Not a listed use | daily tablet | 11.1% weight loss |
 Trulicity | Not a listed use | weekly injection | Not listed |
 Saxenda | Not a listed use | daily injection | 7.4% weight loss |
 Victoza | Not a listed use | daily injection | Not listed |
| Byetta | Not a listed use | twice-daily injection | Not listed |
Sources: FDA label (DailyMed).
Questions to ask your prescriber
- When checking coverage, is my prediabetes counted as a weight-related condition?
- Would a weight-loss brand suit you better than a diabetes brand?
Read the complete Wegovy prescribing information posted on DailyMed.